Renal Nepsiv;-carboxymethyllysine deposition after kidney transplantation

Transplantation

Volumn 86, Issue 2, 2008, Pages 330-335

  Baumann, Marcus ^a,b   Caron, Marjolein ^a,b   Schmaderer, Christoph ^b   Schulte, Christian ^b   Viklicky, Ondreij ^c   Von Weyhern, Claus Werner Hann ^b   Lutz, Jens ^b   Heemann, Uwe ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Advanced glycation endproducts; Megalin; Nepsiv; Carboxymethyllysine; Renal transplanta dysfunction

Indexed keywords

6 N CARBOXYMETHYLLYSINE; CANDESARTAN; CREATININE; LACIDIPINE; MEGALIN; PLACEBO; DRUG DERIVATIVE; LYSINE; N(6) CARBOXYMETHYLLYSINE; N(6)-CARBOXYMETHYLLYSINE;

ADULT; ALLOGRAFT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FIBROSING ALVEOLITIS; FISCHER 344 RAT; GLOMERULUS; GRAFT DYSFUNCTION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY PRESERVATION; KIDNEY PROXIMAL TUBULE; KIDNEY TRANSPLANTATION; LEWIS RAT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ORGAN DONOR; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RECIPIENT; ANIMAL; BIOPSY; CYTOLOGY; INFLAMMATION; KIDNEY; KIDNEY TUBULE; METABOLISM; OXIDATIVE STRESS; SPECIES DIFFERENCE;

ANIMALS; BIOPSY; HUMANS; INFLAMMATION; KIDNEY; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; LDL-RECEPTOR RELATED PROTEIN 2; LYSINE; MALE; OXIDATIVE STRESS; RATS; RATS, INBRED F344; RATS, INBRED LEW; SPECIES SPECIFICITY;

EID: 49249091025     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817ef7a5     Document Type: Article

References (32)

1. Bohlender JM, Franke S, Stein G, et al. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005; 289: F645.
2. Singh R, Barden A, Mori T, et al. Advanced glycation end-products: A review. Diabetologia 2001; 44: 129.
3. Wautier JL, Schmidt AM. Protein glycation: A firm link to endothelial cell dysfunction. Circ Res 2004; 95: 233.
4. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes 1997; 46: 1481.
5. Wautier MP, Chappey O, Corda S, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280: E685.
6. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsilon- carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261: 4889.
7. Baumann M, Stehouwer C, Scheijen J, et al. N{epsilon}- carboxymethyl-lysine is increased in plasma and kidney of spontaneous hypertensive rats during the early development of hypertension and is independent of renal function or oxidative stress. Ann N Y Acad Sci 2008; 1126: 201.
8. Wendt T, Harja E, Bucciarelli L, et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006; 185: 70.
9. Sugimoto H, Grahovac G, Zeisberg M, et al. Renal fibrosis and glomer-ulosclerosis in a new mouse model of diabetic nephropathy and its regressionbybone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 2007; 56: 1825.
10. Zheng F, Zeng YJ, Plati AR, et al. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 2006; 70: 507.
11. Wihler C, Schafer S, Schmid K, et al. Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: Effect of angiotensin-converting enzyme and vasopeptidase inhibition. Diabetologia 2005; 48: 1645.
12. Meng J, Sakata N, Imanaga Y, et al. Carboxymethyllysine in dermal tissues of diabetic and nondiabetic patients with chronic renal failure: Relevance to glycoxidation damage. Nephron 2001; 88: 30.
13. Schram MT, Schalkwijk CG, Bootsma AH, et al. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: The EURODIAB Prospective Complications Study. Hypertension 2005; 46: 232.
14. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996; 39: 149.
15. Miyata T, Ueda Y, Horie K, et al. Renal catabolism of advanced glyca-tion end products: The fate of pentosidine. Kidney Int 1998; 53: 416.
16. Saito A, Takeda T, Sato K, et al. Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases. Ann N Y Acad Sci 2005; 1043: 637.
17. Schleicher E, Weigert C, Rohrbach H, et al. Role of glucoxidation and lipid oxidationin the development of atherosclerosis. Ann NY Acad Sci 2005; 1043: 343.
18. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
19. Hartog JW, Smit AJ, van Son WJ, et al. Advanced glycation end prod-uctsinkidney transplant patients:Aputative roleinthe development of chronic renal transplant dysfunction. Am J Kidney Dis 2004; 43: 966.
20. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ("CAN"). Am J Transplant2007; 7: 518.
21. Szabo A, Lutz J, Schleimer K, et al. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int 2000; 57: 982.
22. Lutz J, Zou H, Liu S, et al. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation2003; 76: 508.
23. Lutz J, Risch K, Liu S, et al. Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy. Kidney Int 2006; 70: 1080.
24. Diamond JR, Tilney NL, Frye J, et al. Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection. Transplantation1992; 54: 710.
25. Hamar P, Liptak P, Heemann U, et al. Ultrastructural analysis of the Fisher to Lewis rat model of chronic allograft nephropathy. Transpl Int 2005; 18: 863.
26. Lutz J, Huang H, Deng M, et al. The effect of FK778 on the progression of chronic allograft nephropathy in a rat model. Transplantation2007; 83: 741.
27. Leheste JR, Rolinski B, Vorum H, et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 1999; 155: 1361.
28. Baidoshvili A, Niessen HW, Stooker W, et al. N(omega)- (carboxymethyl)-lysine depositions in human aortic heart valves: Similarities with atherosclerotic blood vessels. Atherosclerosis 2004; 174: 287.
29. Hartog JW, Voors AA, Schalkwijk CG, et al. Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Eur Heart J 2007; 28: 2879.
30. Kozyraki R, Gofflot F. Multiligand endocytosis and congenital defects: Roles of cubilin, megalin and amnionless. Curr Pharm Des 2007; 13: 3038.
31. Nerlich AG, Schleicher ED. N(epsilon)-(carboxymethyl)lysine in atherosclerotic vascular lesions as a marker for local oxidative stress. Atherosclerosis 1999; 144: 41.
32. Miyata T, van Ypersele de Strihou C, Ueda Y, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478.